User:Mr. Ibrahem/Cyclobenzaprine

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Cyclobenzaprine
Clinical data
Trade namesFlexeril, Amrix, others
AHFS/Drugs.comMonograph
MedlinePlusa682514
Pregnancy
category
Routes of
administration		By mouth
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability33–55%[2][3]
Protein binding93%
MetabolismMajor: CYP3A4, CYP1A2; Minor: CYP2D6, N-demethylation[5]
MetabolitesNorcyclobenzaprine
Elimination half-life32 hours (range 8–37 hours)[4]
ExcretionKidney
Identifiers
  • 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)- N,N-dimethyl-1-propanamine
Chemical and physical data
FormulaC20H21N
Molar mass275.395 g·mol−1
3D model (JSmol)
  • c3cc\2c(\C=C/c1c(cccc1)C/2=C/CCN(C)C)cc3
  • InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3 checkY
  • Key:JURKNVYFZMSNLP-UHFFFAOYSA-N checkY
  (verify)

Cyclobenzaprine, sold under the brand name Flexeril among others, is a medication used for muscle spasms from musculoskeletal conditions of sudden onset.[6] It is not useful in cerebral palsy.[6] It is taken by mouth.[6] Use is not recommended for more than a few weeks.[6]

Common side effects include headache, feeling tired, dizziness, and dry mouth.[6] Serious side effects may include an irregular heart beat.[6] There is no evidence of harm in pregnancy, but it has not been well studied in this population.[6] It should not be used with an MAO inhibitor.[6] How it works is unclear.[6]

Cyclobenzaprine was approved for medical use in the United States in 1977.[6] It is available as a generic medication.[6] In the United States, the wholesale cost per dose is less than US$0.05 as of 2018.[8] In 2017, it was the 43rd most commonly prescribed medication in the United States, with more than 17 million prescriptions.[9][10] It was not available in the United Kingdom as of 2012.[11]

References[edit]

  1. ^ "Cyclobenzaprine Use During Pregnancy". Drugs.com. Archived from the original on 2 June 2019. Retrieved 8 January 2020.
  2. ^ Micromedex® 2010 – DRUGDEX Evaluations (Cyclobenzaprine Hydrochloride)
  3. ^ "Cyclobenzaprine Hydrochloride Tablets USP Revised: April 2005 Rx only". nih.gov. Archived from the original on 21 April 2016. Retrieved 1 October 2016.
  4. ^ Teva Pharmaceuticals USA, Inc (May 2016). "AMR40470 (Amrix) Prescribing Information" (PDF). Archived (PDF) from the original on 22 December 2016. Retrieved 2 February 2017.
  5. ^ Teva Pharmaceuticals USA, Inc (May 2016). "AMR40470 (Amrix) Prescribing Information" (PDF). Archived (PDF) from the original on 22 December 2016. Retrieved 2 February 2017.
  6. ^ a b c d e f g h i j k l m "Cyclobenzaprine Monograph for Professionals". Drugs.com. AHFS. Archived from the original on 23 December 2018. Retrieved 22 December 2018.
  7. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 26 September 2020. Retrieved 9 September 2020.
  8. ^ "NADAC as of 2018-12-19". Centers for Medicare and Medicaid Services. Archived from the original on 19 December 2018. Retrieved 22 December 2018.
  9. ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  10. ^ "Cyclobenzaprine - Drug Usage Statistics". ClinCalc. Archived from the original on 12 April 2020. Retrieved 11 April 2020.
  11. ^ "Fibromyalgia, psychiatric comorbidity, and the somatosensory cortex". British Journal of Medical Practitioners. 5 (2): a522. 2012. Archived from the original on 23 December 2018. Retrieved 22 December 2018.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Cyclobenzaprine&oldid=1204892418"